Skip to search formSkip to main contentSkip to account menu

Dipeptidyl Peptidase-4 Inhibitor

Known as: DPP-4 Inhibitor 
Any inhibitor of the proline-specific serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. DPP-4 inhibitors bind to DPP-4 and… 
National Institutes of Health

Related topics

Related topics

3 relations
Dipeptidyl Peptidase 4 Inhibitor [EPC]Dipeptidyl Peptidase 4 Inhibitors [MoA]Dipeptidyl-Peptidase IV Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial…
On page 2048 of the article cited above, the word “increases” was corrected to read “decreases.” The … 
Review
2018
Review
2018
The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus
Abstract The purpose of this study was to examine the association of dipeptidyl peptidase-4 inhibitors (DPP4Is) with joint pain… 
2017
2017
Do DPP-4 inhibitors improve endothelial cell function?
DPP-4 inhibitors have been used to treat patients with type 2 diabetes mellitus. These agents not only provide glycemic control… 
2016
2016
Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients
Objective: This retrospective cohort study aimed to investigate the significance of dipeptidyl peptidase-4 (DPP- 4) inhibitor… 
2016
2016
Glycemic control and cost-effectiveness attained by the drug utilization of oral antidiabetic agents in a tertiary care hospital in South India
Background: Diabetes mellitus require lifelong intervention and Kerala has high prevalence. New expensive agents require… 
Review
2016
Review
2016
Mini-review: Pharmacokinetics of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor
The dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral hypoglycemic drugs which have been in clinical use for the past 10… 
Review
2015
Review
2015
Role of Sitagliptin-Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes Mellitus-An Overview
Diabetes mellitus is major health problem and increasing cause of morbidity and mortality. Type 1 diabetes mellitus accounts for… 
2014
2014
Effect of DPP-4 inhibitor saxagliptin on endothelium-dependent vasodilation in patients with type 2 diabetes
Objective To investigate the effect of DPP-4 inhibitor saxagliptin on endothelium-dependent flow mediated vasodilatation( FMD) in… 
2013
2013
Combination of PPAR-α Agonist and DPP-4 Inhibitor: A Novel Therapeutic Approach in the Management of Diabetic Nephropathy
The present study investigated the combined effect of fenofibrate (PPAR-α agonist) and saxagliptin (DPP-4 inhibitor) in diabetes… 
2009
2009
Erratum to: Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus